Reaffirmed MACI full-year revenue growth in the low 20% range, or $237.5 to $239.5 million; Reaffirmed full-year profitabilty guidance of 74% gross margin and adjusted EBITDA margin of 26%
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- VCEL Upcoming Earnings Report: What to Expect?
- Vericel price target lowered to $41 from $46 at Truist
- Vericel’s Promising Growth: Buy Rating Backed by MACI Revenue Surge and Successful MACI Arthro Launch
- Vericel’s Strategic Growth and Market Expansion Drive Buy Rating
- Vericel downgraded to Neutral from Buy at BTIG